Kymera Stock Soars on Breakthrough Eczema Drug Results
Kymera Therapeutics (KYMR) shares surge after Phase 1b trial shows KT-621 oral pill achieves Dupixent-like efficacy in treating moderate to severe eczema with favorable safety profile.
Kymera Therapeutics (KYMR) shares surge after Phase 1b trial shows KT-621 oral pill achieves Dupixent-like efficacy in treating moderate to severe eczema with favorable safety profile.
Ocular Therapeutix (OCUL) shares surge 27% after announcing plans to fast-track FDA submission for Axpaxli, a promising new treatment for wet age-related macular degeneration affecting millions.
Dyne Therapeutics' experimental DMD treatment shows strong results in late-stage trial, potentially offering more effective alternative to current controversial therapies with 10x higher dystrophin levels.
New data confirms Arcellx’s anito-cel is a powerful and safe CAR-T cell therapy for relapsed or refractory multiple myeloma, showing deep, durable responses.
Fulcrum's (FULC) experimental oral treatment for sickle cell disease demonstrates stronger fetal hemoglobin increases at 20mg dose, though researchers emphasize it's not a cure for the genetic disorder.
CooperCompanies initiates strategic review exploring partnerships and divestitures while appointing Colleen Jay as new board chair. Q4 revenue up 5% to $1.07B.